{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:10:56Z","timestamp":1783030256034,"version":"3.54.6"},"reference-count":20,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Research Supporting project by the National Natural Science Foundation of China","award":["No. 82200734"],"award-info":[{"award-number":["No. 82200734"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth factor receptor family, plays a crucial role in cell growth, differentiation, and tissue repair. Increased FGFR4 expression has been detected in various cancers, including lung, liver, kidney and pancreatic cancer, making it a potential drug target. In this study, we conducted a structure-based virtual screening campaign to identify potential FGFR4 inhibitors. The retained compounds were further filtered based on pan assay interference compounds (PAINS) and absorption, distribution, metabolism, excretion, and toxicity (ADME\/T) properties, leading to the identification of two promising candidates: MFCD00832235 and MFCD00204244. Quantum mechanical (QM) calculations revealed a large Highest Occupied Molecular Orbital (HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO) (HUMO-LUMO) gaps for both compounds, indicating high dynamic stability and low chemical reactivity. Moreover, the stability of MFCD00832235 and MFCD00204244 at the adenosine triphosphate (ATP)-binding site of FGFR4 was confirmed through molecular dynamics (MD) simulations. The molecular mechanics Poisson-Boltzmann surface area (MM\/PBSA) approach predicted favorable binding free energy values for both compounds with the target protein. <jats:italic>In vitro<\/jats:italic> assay revealed that MFCD00832235 and MFCD00204244 inhibited the growth of HepG2 cells with IC<jats:sub>50<\/jats:sub> values of 47.42\u00a0\u00b1\u00a012.93 \u00b5M and 77.83\u00a0\u00b1\u00a019.17 \u00b5M, respectively. Overall, this study suggested that MFCD00832235 and MFCD00204244 were potential FGFR4 inhibitors and may serve as start points for developing novel modulators of FGFR4 for cancer treatment, particularly hepatocellular carcinoma.<\/jats:p>","DOI":"10.7717\/peerj.19183","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T08:00:36Z","timestamp":1750233636000},"page":"e19183","source":"Crossref","is-referenced-by-count":1,"title":["Structure-based identification of potent fibroblast growth factor receptor 4 (FGFR4) inhibitors as potential therapeutics for hepatocellular carcinoma"],"prefix":"10.7717","volume":"13","author":[{"given":"Lin","family":"Fan","sequence":"first","affiliation":[{"name":"Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[{"name":"Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhu","family":"Peng","sequence":"additional","affiliation":[{"name":"Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Fu","sequence":"additional","affiliation":[{"name":"Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Ye","sequence":"additional","affiliation":[{"name":"Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei, China"},{"name":"The 3rd Xiangya Hospital of Central South University, NHC Key Laboratory of Translational Research on Transplantation Medicine, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"11","key":"10.7717\/peerj.19183\/ref-1","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/1541-7786.MCR-10-0168","article-title":"Roles of fibroblast growth factor receptors in carcinogenesis","volume":"8","author":"Haugsten","year":"2010","journal-title":"Molecular Cancer Research"},{"issue":"1","key":"10.7717\/peerj.19183\/ref-2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jhep.2008.08.015","article-title":"Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis, and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention","volume":"50","author":"Ho","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.7717\/peerj.19183\/ref-3","doi-asserted-by":"publisher","first-page":"672935","DOI":"10.3389\/fcell.2021.672935","article-title":"The multifunctional contribution of FGF signaling to cardiac development, homeostasis, disease and repair","volume":"9","author":"Khosravi","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.7717\/peerj.19183\/ref-4","doi-asserted-by":"publisher","first-page":"107590","DOI":"10.1016\/j.pharmthera.2020.107590","article-title":"FGFR4: a promising therapeutic target for breast cancer and other solid tumors","volume":"214","author":"Levine","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"10.7717\/peerj.19183\/ref-5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/joim.13767","article-title":"Targeting the FGF19\u2013FGFR4 pathway for cholestatic, metabolic, and cancerous diseases","volume":"295","author":"Li","year":"2024","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.7717\/peerj.19183\/ref-6","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/molecules25061375","article-title":"A review on applications of computational methods in drug screening and design","volume":"25","author":"Lin","year":"2020","journal-title":"Molecules"},{"key":"10.7717\/peerj.19183\/ref-7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fcell.2020.00095","article-title":"Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression","volume":"8","author":"Liu","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.7717\/peerj.19183\/ref-8","doi-asserted-by":"publisher","first-page":"633453","DOI":"10.3389\/fphar.2021.633453","article-title":"Novel regulatory factors and small-molecule inhibitors of FGFR4 in cancer","volume":"9","author":"Liu","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10.7717\/peerj.19183\/ref-9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jmat.2017.08.002","article-title":"Materials discovery and design using machine learning","volume":"3","author":"Liu","year":"2017","journal-title":"Journal of Materiomics"},{"issue":"4","key":"10.7717\/peerj.19183\/ref-10","doi-asserted-by":"publisher","first-page":"e06605","DOI":"10.1016\/j.heliyon.2021.e06605","article-title":"Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors","volume":"7","author":"Moussa","year":"2021","journal-title":"Heliyon"},{"issue":"10","key":"10.7717\/peerj.19183\/ref-11","doi-asserted-by":"publisher","first-page":"8445","DOI":"10.1021\/acs.jmedchem.4c00758","article-title":"Discovery of 2, 6-Naphthyridine analogues as selective FGFR4 inhibitors for hepatocellular carcinoma","volume":"67","author":"Oh","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.7717\/peerj.19183\/ref-12","doi-asserted-by":"publisher","first-page":"e63695","DOI":"10.1371\/journal.pone.0063695","article-title":"FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer","volume":"8","author":"Pel\u00e1ez-Garc\u00eda","year":"2013","journal-title":"PLOS ONE"},{"issue":"6","key":"10.7717\/peerj.19183\/ref-13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/cells8060536","article-title":"FGF19\u2013FGFR4 signaling in hepatocellular carcinoma","volume":"8","author":"Raja","year":"2019","journal-title":"Cell"},{"key":"10.7717\/peerj.19183\/ref-14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","article-title":"Computational approaches streamlining drug discovery","volume":"616","author":"Sadybekov","year":"2023","journal-title":"Nature"},{"issue":"17","key":"10.7717\/peerj.19183\/ref-15","doi-asserted-by":"publisher","first-page":"11110","DOI":"10.1074\/jbc.M808747200","article-title":"FGF15\/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action","volume":"284","author":"Shin","year":"2009","journal-title":"Journal of Biological Chemistry"},{"issue":"12","key":"10.7717\/peerj.19183\/ref-16","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1158\/2159-8290.CD-19-1156","article-title":"Precision oncology for hepatocellular cancer: slivering the liver by FGF19\u2013FGFR4\u2013KLB pathway inhibition","volume":"9","author":"Subbiah","year":"2019","journal-title":"Cancer Discovery"},{"issue":"1","key":"10.7717\/peerj.19183\/ref-17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3390\/ijms13010427","article-title":"Adaptation of high-throughput screening in drug discovery-toxicological screening tests","volume":"13","author":"Szyma\u0144ski","year":"2012","journal-title":"International Journal of Molecular Sciences"},{"issue":"12","key":"10.7717\/peerj.19183\/ref-18","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1002\/j.1460-2075.1992.tb05526.x","article-title":"Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction","volume":"11","author":"Vainikka","year":"1992","journal-title":"The EMBO Journal"},{"issue":"18","key":"10.7717\/peerj.19183\/ref-19","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1242\/dev.125.18.3615","article-title":"FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung","volume":"125","author":"Weinstein","year":"1998","journal-title":"Development"},{"issue":"1","key":"10.7717\/peerj.19183\/ref-20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/19183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/19183.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/19183.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/19183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T08:00:48Z","timestamp":1750233648000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/19183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":20,"alternative-id":["10.7717\/peerj.19183"],"URL":"https:\/\/doi.org\/10.7717\/peerj.19183","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"e19183"}}